for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Amarin Corporation plc (ADR)

AMRN.O

Latest Trade

4.59USD

Change

-0.01(-0.11%)

Volume

3,328,166

Today's Range

4.51

 - 

4.70

52 Week Range

3.36

 - 

9.25

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
4.60
Open
4.60
Volume
3,328,166
3M AVG Volume
121.45
Today's High
4.70
Today's Low
4.51
52 Week High
9.25
52 Week Low
3.36
Shares Out (MIL)
394.77
Market Cap (MIL)
1,813.98
Forward P/E
-35.35
Dividend (Yield %)
--

Next Event

Amarin Corporation PLC Annual Shareholders Meeting

Latest Developments

More

Amarin Reports Q1 Revenue Of $142.2 Mln

Amarin Receives Great Britain Marketing Authorization For Vazkepa

Amarin Says Board Has Appointed Karim Mikhail To Succeed Thero As Next President, CEO

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Amarin Corporation plc (ADR)

Amarin Corporation plc is a biopharmaceutical company with operations in lipid science focused on the commercialization and development of therapeutics for cardiovascular health. The Company operates through the development and commercialization of Vascepa segment. The Company's lead product, Vascepa (icosapent ethyl) capsule, is approved by the United States Food and Drug Administration (FDA) for use as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. This indication for Vascepa, known as the MARINE indication, is based primarily on the results from the MARINE study of Vascepa in this approved patient population. The Company sells Vascepa principally to wholesalers, as well as selected regional wholesalers and specialty pharmacy providers, or collectively, its distributors, which in turn resell Vascepa to retail pharmacies for resale to patients and healthcare providers.

Industry

Biotechnology & Drugs

Contact Info

Gemini House, Bartholomews Walk

FK7 9JQ

Ireland

+353.1.6699020

http://www.amarincorp.com/

Executive Leadership

Lars G. Ekman

Non-Executive Independent Chairman of the Board

John F. Thero

President, Chief Executive Officer, Director

Michael Wayne Kalb

Chief Financial Officer, Senior Vice President, Assistant Secretary

Joseph T. Kennedy

Executive Vice President, General Counsel, Secretary, Strategic Initiatives

Stephen B. Ketchum

President - Research and Development, Senior Vice President, Chief Scientific Officer

Key Stats

2.44 mean rating - 9 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

0.2K

2019

0.4K

2020

0.6K

2021(E)

0.6K
EPS (USD)

2018

-0.390

2019

-0.070

2020

-0.050

2021(E)

-0.130
Price To Earnings (TTM)
2,167.45
Price To Sales (TTM)
3.02
Price To Book (MRQ)
2.86
Price To Cash Flow (TTM)
610.77
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
0.14
Return on Equity (TTM)
0.10

Latest News

Latest News

Amarin's heart drug Vazkepa gets European Commission approval

The European Commission has granted Amarin Corporation Plc's fish-oil derived heart drug Vazkepa marketing authorization in the European Union, the drugmaker said on Tuesday.

UPDATE 1-European Commission clears Amarin's fish-oil derived heart drug Vazkepa

Amarin Corporation Plc said on Tuesday that the European Commission has granted its fish-oil derived heart drug Vazkepa a marketing authorization in the European Union.

Fed Circuit swiftly rejects Amarin bid to save heart drug patents on appeal

A federal appeals court on Thursday dealt a major setback to pharmaceutical company Amarin Corp, affirming a patent ruling that opened the door to generic versions of its heart drug Vascepa.

Amarin tries to reverse damage from Vascepa patent ruling

Pharmaceutical company Amarin Corp will ask an appeals court on Wednesday to undo a ruling that invalidated its patents on its heart drug Vascepa and sent its stock price into a nosedive.

BRIEF-Amarin Announces Patent Litigation Settlement Agreement With Apotex

* AMARIN ANNOUNCES PATENT LITIGATION SETTLEMENT AGREEMENT WITH APOTEX INC

BRIEF-Amarin Says Vascepa Shows Significant Cardiovascular Risk Reduction In People With Diabetes

* VASCEPA® (ICOSAPENT ETHYL) SHOWS SIGNIFICANT CARDIOVASCULAR RISK REDUCTION IN PEOPLE WITH DIABETES IN PRESPECIFIED AND POST HOC SUBGROUP ANALYSES OF LANDMARK REDUCE-IT® STUDY

BRIEF-Amarin Plans To Increase Vascepa Promotion And Education

* AMARIN PLANS TO INCREASE VASCEPA® (ICOSAPENT ETHYL) PROMOTION AND EDUCATION

BRIEF-Amarin Supports Trial To Investigate Effects Of Vascepa In Treatment Of COVID-19

* AMARIN SUPPORTS TRIAL TO INVESTIGATE THE EFFECTS OF VASCEPA® (ICOSAPENT ETHYL) IN THE TREATMENT OF COVID-19 Source text for Eikon: Further company coverage:

BRIEF-Amarin Reports Q1 2020 Financial Results

* AMARIN REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS AND PROVIDES UPDATE ON OPERATIONS

BRIEF-Amarin Corp Reports $150 Mln Total Revenue For 3 Months Ended March 31

* BASED ON A PRELIMINARY ESTIMATE, ITS TOTAL REVENUE, NET FOR THREE MONTHS ENDED MARCH 31 WAS APPROXIMATELY $150 MILLION

Amarin loses patent lawsuit on main drug, shares tumble

Shares of Amarin Corp plunged nearly 70% on Tuesday after the drugmaker lost a major U.S. patent battle for its heart drug Vascepa, opening the door for generic competition to its main revenue contributor.

BRIEF-HLS Therapeutics Comments On U.S. District Court Decision On Amarin Patents

* HLS THERAPEUTICS COMMENTS ON U.S. DISTRICT COURT DECISION ON AMARIN PATENTS

IN BRIEF: Amarin plunges after surprise patent ruling on heart drug

A judge ruled on Monday that patents covering the Amarin Corporation plc heart drug Vascepa were invalid, giving two generic drug companies an opening to sell their own low-cost versions years earlier than industry observers had expected.

BRIEF-Amarin Says Will Continue With Promotional Efforts For Vascepa In Treating Indicated Patients At High Risk Of Cardiovascular Events

* AMARIN CORPORATION - WILL PURSUE ALL AVAILABLE REMEDIES, INCLUDING AN APPEAL OF COURT'S DECISION

BRIEF-Amarin Says Eicosapentaenoic Acid Levels From Vascepa In Reduce-It® Strongly Correlated With Cardiovascular Outcomes

* EICOSAPENTAENOIC ACID (EPA) LEVELS FROM VASCEPA® (ICOSAPENT ETHYL) IN REDUCE-IT® STRONGLY CORRELATED WITH CARDIOVASCULAR OUTCOMES

BRIEF-Amarin Corp PLC Files For Potential Mixed Shelf Offering Size Not Disclosed - SEC Filing

* AMARIN CORPORATION PLC FILES FOR POTENTIAL MIXED SHELF OFFERING; SIZE NOT DISCLOSED - SEC FILING Source text: (http://bit.ly/2PtiTfe) Further company coverage:

BRIEF-Amarin Corp Qtrly Shr $0.02

* QTRLY SHR $0.02; QTRLY ADJ. SHR $0.04; QTRLY NET REV $143.3 MLN, UP 85%

Amarin beats quarterly revenue estimates on strong Vascepa uptake

Amarin Corp Plc <AMRN.O> beat estimates for fourth-quarter revenue on Tuesday, helped by strong demand for its fish-oil derived therapy Vascepa that recently won U.S. approval for expanded heart benefit claims.

FDA says Amarin can market fish-oil derived therapy for reducing heart attack risk

U.S. health regulators on Friday approved expanding the heart benefit claims Amarin Corp can make in promoting its drug Vascepa to include reducing the risk of heart attacks and strokes in high-risk patients, opening a multibillion-dollar market opportunity.

FDA panel unanimously backs expanding use of Amarin's heart drug Vascepa

A panel of experts to the U.S. FDA recommended allowing Amarin Corp Plc's fish-oil derived drug to be used as an add-on therapy for reducing the chance of heart attacks and strokes in high-risk patients with cardiovascular disease.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up